Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | WGS reveals sequential & persistent loss of BCMA and GPRC5D after bispecific antibodies in myeloma

In this video, Leo Rasche, MD, University of Würzburg, Würzburg, Germany, discusses a recent study in which whole-genome sequencing (WGS) data demonstrated a loss of BCMA and GPRC5D in patients with relapsed/refractory (R/R) multiple myeloma treated with bispecific antibodies. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.